Research Site

Kawagoe-shi 350-8550

3 studies enrolling now · 9 studies all time

What they study most

Generalized Myasthenia Gravis, Hormone-Sensitive Prostate Cancer, Metastatic Castration-Sensitive Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder, Non-small Cell Lung Cancer, Non-squamous Non-small Cell Lung Cancer, Prostate Cancer

Studies at this site

• A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation — Recruiting now
• A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) — Recruiting now
• A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC — Recruiting now
• Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents — Running, not enrolling
• Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer — Running, not enrolling
• Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency — Running, not enrolling
• An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD — Completed
• Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis — Completed
• Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study) — Completed